These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19151610)

  • 1. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine.
    Hope TA; Herfkens RJ; Denianke KS; LeBoit PE; Hung YY; Weil E
    Invest Radiol; 2009 Mar; 44(3):135-9. PubMed ID: 19151610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study.
    Janus N; Launay-Vacher V; Karie S; Clement O; Ledneva E; Frances C; Choukroun G; Deray G
    Eur J Radiol; 2010 Feb; 73(2):357-9. PubMed ID: 19128909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
    Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
    Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
    Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J
    J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
    Bryant BJ; Im K; Broome DR
    Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
    Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis: center case review.
    Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
    J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
    Wertman R; Altun E; Martin DR; Mitchell DG; Leyendecker JR; O'Malley RB; Parsons DJ; Fuller ER; Semelka RC
    Radiology; 2008 Sep; 248(3):799-806. PubMed ID: 18632533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large sample of nephrogenic systemic fibrosis cases from a single institution.
    Lee CU; Wood CM; Hesley GK; Leung N; Bridges MD; Lund JT; Lee PU; Pittelkow MR
    Arch Dermatol; 2009 Oct; 145(10):1095-102. PubMed ID: 19841395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
    Rydahl C; Thomsen HS; Marckmann P
    Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis.
    Kennedy C; Magee C; Eltayeb E; Gulmann C; Conlon PJ
    Ir Med J; 2010; 103(7):208-10. PubMed ID: 20845600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan.
    Chen W; Huang SL; Huang CS; Tsai MC; Lai HM; Lui CC; Eng HL; Chang HW; Lee CH; Chuang FR
    Eur J Dermatol; 2009; 19(1):44-9. PubMed ID: 19059824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
    Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis.
    Steger-Hartmann T; Hofmeister R; Ernst R; Pietsch H; Sieber MA; Walter J
    Invest Radiol; 2010 Sep; 45(9):520-8. PubMed ID: 20644486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
    Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
    J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.